TOP NEWS

Amgen And AbbVie In Legal Settlement

Thousand Oaks-based Amgen and AbbVie have settled a series of lawsuits against each other, saying this morning that they have agreed to resolve all pending litigation regarding AMGEVITA/AMJEVITA, a biosimilar which is based on AbbVie's Humira (adalimumab). According to the two, AbbVie will grant a patent license for use and sale of the compound worldwide, on a country-by-country basis. The two have also agreed to dismiss all pending litigation over the biosimilar. As a result of the settlement, Amgen said it expects to launch its product in Europe in October of 2018, and its product for the United States in 2023. Financial details of the settlement were not announced.